Lithium naphthalenide | 14474-59-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: Lithium naphthalenide
• 英文别名: lithium;1H-naphthalen-1-ide
• CAS: 14474-59-0
• 化学式: C10H7Li
• 分子量: 134.1
• InChiKey: GQNMAZUQZDEAFI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.36
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  Lithium naphthalenide 、 (1R*,2R*,5S*,6R*)-8-Benzyl-1-phenyl-6-phenylsulphonyl-8-azabicyclo[3.2.1]octan-2-ol 在 氯化铵 、 乙酸乙酯 、 水 、 magnesium sulfate 、 silica gel 、 ethyl acetate iso-hexanes 作用下， 以 四氢呋喃 为溶剂， 以to yield the title compound (14.3 g, 84.6%)的产率得到(1R,2R,5R)-8-benzyl-1-phenyl-8-azabicyclo[3.2.1]octan-2-ol
  参考文献：
  名称：

  Azabicyclic ether derivatives and their use as therapeutic agents

  摘要：

  本发明涉及公式(I)的化合物：其中X代表氢，C1-4烷基，可选地被羟基，甲氧基或苄氧基取代，或CO2（C1-2烷基）; Z为—CR9R10CH2—或—CH2CR9R10—; 而R1、R2、R3、R4、R5和R6如本文所定义。这些化合物特别适用于治疗或预防抑郁症、焦虑症、疼痛、炎症、偏头痛、呕吐或带状疱疹后神经痛。

  公开号：

  US06727249B2

文献信息

• Novel lipid complexes for transferring at least one therapeutically active substance, in particular a polynucleotide, into a target cell, and use in gene therapy
  申请人：——

  公开号：US20020025920A1

  公开（公告）日：2002-02-28

  The present invention relates to a complex comprising at least a lipid and at least a therapeutically active substance for transferring the therapeutically active substance into a target cell. The present invention also relates to a method of transferring a therapeutically active substance into cells.

  本发明涉及至少包括脂质和至少一种治疗活性物质的复合物，用于将治疗活性物质转移至靶细胞。本发明还涉及将治疗活性物质转移至细胞的方法。
• PIPERIDINE DERIVATIVES AND THEIR USE AS TACHYKININ ANTAGONISTS
  申请人：——

  公开号：US20020052504A1

  公开（公告）日：2002-05-02

  Substituted piperidine derivatives of structural formula (I) wherein R1 represents a hydrogen atom or a methyl or trifluoromethyl group; R2 represents a hydrogen or halogen atom, and R3 represents a hydrogen or halogen atom, and pharmaceutically acceptable salts thereof are tachykinin receptor antagonists of use, for example, in the treatment or prevention of pain, inflammation, migraine, emesis, postherpetic neuralgia, depression and anxiety.

  结构式(I)的取代哌啶衍生物，其中R1代表氢原子或甲基或三氟甲基基团；R2代表氢原子或卤素原子，R3代表氢原子或卤素原子，以及其药学上可接受的盐是速激肽受体拮抗剂，例如，用于治疗或预防疼痛、炎症、偏头痛、恶心、带状疱疹后神经痛、抑郁和焦虑。
• Benzoamide piperidine containing compounds and related compounds
  申请人：——

  公开号：US20030087925A1

  公开（公告）日：2003-05-08

  The present invention relates to certain benzoamide piperidine containing compounds and related compounds that exhibit activity as NK-1 receptor antagonists, (e.g., substance P receptor antagonists), to pharmaceutical compositions containing them, and to their use in the treatment and prevention of central nervous system disorders, inflammatory disorders, cardiovascular disorders, ophthalmic disorders, gastrointestinal disorders, disorders caused by helicobacter pylori, disorders of the immune system, urinary incontinence, pain, migraine, emesis, angiogenesis and other disorders.

  本发明涉及某些含有苯甲酰胺哌啶类化合物和相关化合物，其表现为NK-1受体拮抗剂（例如，物质P受体拮抗剂），以及含有它们的制药组合物，并且它们在治疗和预防中枢神经系统疾病、炎症性疾病、心血管疾病、眼科疾病、胃肠疾病、幽门螺杆菌引起的疾病、免疫系统疾病、尿失禁、疼痛、偏头痛、呕吐、血管生成和其他疾病中的使用。
• Substituted 3-(benzylamino)piperidine derivatives and their use as therapeutic agents
  申请人：Merck Sharp & Dohme Limited

  公开号：US06214846B1

  公开（公告）日：2001-04-10

  The present invention relates to compounds of formula (I), wherein R1 represents a fluoroC1-2alkoxy group; and R2 represents a hydrogen or halogen atom or a C1-4alkyl, C1-4alkoxy, fluoroC1-4alkyl or fluoroC1-4alkoxy group; or a pharmaceutically acceptable salt thereof. The compounds are of particular use in the treatment or prevention of pain or inflammation, migraine, emesis, postherpetic neuralgia, depression or anxiety.

  本发明涉及式（I）的化合物，其中R1代表氟基C1-2烷氧基团；R2代表氢原子或卤素原子或C1-4烷基，C1-4烷氧基，氟基C1-4烷基或氟基C1-4烷氧基团；或其药学上可接受的盐。该化合物特别适用于治疗或预防疼痛或炎症、偏头痛、呕吐、带状疱疹后神经痛、抑郁症或焦虑症。
• Use of NK-1 receptor antagonists for treating cognitive disorders
  申请人：Merck Sharp & Dohme Limited

  公开号：US06271230B1

  公开（公告）日：2001-08-07

  The present invention provides methods for the treatment or prevention of cognitive disorders which comprises oral administration of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist and pharmaceutical compositions comprising such a NK-1 receptor antagonist.

  本发明提供了治疗或预防认知障碍的方法，其中包括口服具有口服活性、长效、能穿透中枢神经系统的NK-1受体拮抗剂，并且还提供了包含这种NK-1受体拮抗剂的制药组合物。